Frequently Asked Questions
The sexually transmitted diseases (STD) testing market size will be worth USD 1,58,734.55 million by 2029.
The growth rate of the sexually transmitted diseases (STD) testing market is 7.85%.
The rise in sexually transmitted diseases prevalence globally, increased patient awareness through education campaigns, and a surge in government initiatives are the growth drivers of the sexually transmitted diseases (STD) testing market.
Major companies in the sexually transmitted diseases (STD) testing market are bioMérieux SA, BD, Hologic, Inc., OraSure Technologies, Inc., Bio-Rad Laboratories, Inc., Abbott. Merck & Co. Inc., Johnson & Johnson Services, Inc, GlaxoSmithKline Plc., Allergen, Bayer AG, Bristol-Myers Squibb Company, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Sorrento Therapeutics, Inc., WEX Pharmaceuticals Inc., Zynerba Pharmaceuticals, Inc., Medtronic, Boston Scientific Corporation, Halyard Health, Inc. and Neurotech Na, Inc.
Disease type and location of testing are the factors on which the sexually transmitted diseases (STD) testing market research is based.
